title: Three key antipsychotics lose patent protection.
authors.forename: Brian
authors.initials: B
authors.lastname: Albright
mesh_terms: D014150:Antipsychotic Agents / Q000191:economics* / Q000600:supply & distribution; D001569:Benzodiazepines / Q000191:economics*; D003987:Dibenzothiazepines / Q000191:economics*; D055808:Drug Discovery; D016568:Drugs, Generic / Q000191:economics / Q000600:supply & distribution; D005569:Formularies as Topic; D006801:Humans; D008484:Medicaid / Q000191:economics; D000077152:Olanzapine; D010330:Patents as Topic; D010879:Piperazines / Q000191:economics*; D000069348:Quetiapine Fumarate; D013844:Thiazoles / Q000191:economics*; D014481:United States
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D016568:Drugs, Generic; D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D000077152:Olanzapine